GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved anywhere in the world. i Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “As the second most ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

We remind investors that in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

Clinical trial investigators and the company believe these results could support making the GSK drug, Blenrep, a new standard of care treatment for this type of blood cancer. The new trial results ...

GSK’sGSK-2.45%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...

You can reach Andrew on Signal at drewqjoseph.45. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was ...